Immune responses in cancer

被引:119
作者
Adam, JK
Odhav, B
Bhoola, KD
机构
[1] Univ Western Australia, Sir Charles Gairdiner Hosp, Asthma & Allergy Res Inst, Nedlands, WA 6009, Australia
[2] Durban Inst Technol, Dept Biol Sci, Durban, South Africa
[3] Durban Inst Technol, Dept Med Sci, Durban, South Africa
基金
英国医学研究理事会; 新加坡国家研究基金会;
关键词
carcinogenesis; immunity; immunotherapy; tumour antigens and surveillance; vaccines;
D O I
10.1016/S0163-7258(03)00056-1
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The complex of Immoral factors and immune cells comprises two interleaved systems, innate and acquired. Immune cells scan the occurrence of any molecule that it considers to be nonself. Transformed cells acquire antigenicity that is recognized as nonself. A specific immune response is generated that results in the proliferation of antigen-specific lymphocytes. Immunity is acquired when antibodies and T-cell receptors are expressed and up-regulated through the formation and release of lymphokines, chemokines, and cytokines. Both innate and acquired immune systems interact to initiate antigenic responses against carcinomas. A new approach to the treatment of cancer has been immunotherapy, which aims to up-regulate the immune system in order that it may better control carcinogenesis. Currently, several forms of immunotherapy that use natural biological substances to activate the immune system are being explored therapeutically. The various forms of immunotherapy fall into three main categories: monoclonal antibodies, immune response modifiers, and vaccines. While these modalities have individually shown some promise, it is likely that the best strategy to combat cancer may require multiple immunotherapeutic strategies in order to demonstrate benefit in different patient populations. It may be that the best results are obtained with vaccines in combination with a variety of immunotherapy combinations. Another potent strategy may be in combining with more traditional cancer drugs as evidenced from the benefit derived from enhancing the efficacy of chemotherapy with cytokines. Through such concerted efforts, a durable, therapeutic antitumour immune response may be achieved and maintained over the course of a patient's lifespan. (C) 2003 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:113 / 132
页数:20
相关论文
共 123 条
  • [41] Gri G, 2002, CANCER RES, V62, P4390
  • [42] Cell damage-induced conformational changes of the pro-apoptotic protein bak in vivo precede the onset of apoptosis
    Griffiths, GJ
    Dubrez, L
    Morgan, CP
    Jones, NA
    Whitehouse, J
    Corfe, BM
    Dive, C
    Hickman, JA
    [J]. JOURNAL OF CELL BIOLOGY, 1999, 144 (05) : 903 - 914
  • [43] HEMATOPOIETIC GROWTH-FACTORS - BIOLOGY AND CLINICAL-APPLICATIONS
    GROOPMAN, JE
    MOLINA, JM
    SCADDEN, DT
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (21) : 1449 - 1459
  • [44] IMMUNE SURVEILLANCE WITHOUT IMMUNOGENICITY
    GROSSMAN, Z
    HERBERMAN, RB
    [J]. IMMUNOLOGY TODAY, 1986, 7 (05): : 128 - 131
  • [45] Gupta S, 2002, NATL MED J INDIA, V15, P202
  • [46] MOLECULAR MECHANISMS OF SIGNAL TRANSDUCTION IN MACROPHAGES
    HAMILTON, TA
    ADAMS, DO
    [J]. IMMUNOLOGY TODAY, 1987, 8 (05): : 151 - 158
  • [47] Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumor cell vaccine: first randomized phase III trials show promise
    Hanna, MG
    Hoover, HC
    Vermorken, JB
    Harris, JE
    Pinedo, HM
    [J]. VACCINE, 2001, 19 (17-19) : 2576 - 2582
  • [48] HEIDENREICH S, 1989, J IMMUNOL, V143, P1198
  • [49] Enhancement of complement-dependent cytotoxicity by polyvalent melanoma cell vaccine (CancerVax): Correlation with survival
    Hsueh, EC
    Famatiga, E
    Gupta, RK
    Qi, K
    Morton, DL
    [J]. ANNALS OF SURGICAL ONCOLOGY, 1998, 5 (07) : 595 - 602
  • [50] Hwang C, 1999, CURR OPIN MOL THER, V1, P471